ICON Public FY2024 EPS Estimate Raised by William Blair

ICON Public Limited (NASDAQ:ICLR) – William Blair boosted their FY2024 earnings per share (EPS) estimates for ICON Public in a report released on Wednesday, January 15th. William Blair analyst M. Smock now forecasts that the medical research company will earn $13.55 per share for the year, up from their previous forecast of $13.40. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.41 per share. William Blair also issued estimates for ICON Public’s FY2025 earnings at $13.33 EPS.

ICLR has been the topic of a number of other reports. Evercore ISI reduced their target price on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. TD Cowen cut their price objective on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Redburn Atlantic began coverage on shares of ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 target price for the company. Robert W. Baird dropped their price objective on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Finally, Barclays decreased their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ICON Public currently has an average rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Stock Performance

Shares of ICLR stock opened at $198.11 on Monday. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The stock has a market cap of $16.34 billion, a PE ratio of 22.09, a P/E/G ratio of 1.59 and a beta of 1.20. The stock has a fifty day moving average price of $209.71 and a 200 day moving average price of $267.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the company earned $3.10 earnings per share. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year.

Institutional Investors Weigh In On ICON Public

Hedge funds have recently made changes to their positions in the business. Avior Wealth Management LLC boosted its stake in ICON Public by 76.0% during the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock valued at $187,000 after purchasing an additional 386 shares in the last quarter. Park Place Capital Corp lifted its position in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares during the last quarter. Steph & Co. boosted its stake in shares of ICON Public by 3.7% during the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after acquiring an additional 55 shares in the last quarter. GAMMA Investing LLC raised its position in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the period. Finally, Foyston Gordon & Payne Inc purchased a new stake in shares of ICON Public during the third quarter valued at $11,672,000. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.